Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 105
Price: $ 3500


GlobalData, the Industry analysis specialist, has released its new report, “Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global Heart Failure therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global Heart Failure therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Heart Failure sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global Heart Failure (HF) therapeutics market valued at $3,269.0m in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010. GlobalData analysis suggests that the global HF therapeutics market will grow at a high CAGR of 2.5% over the next eight years, to reach $5,104.1m by 2018. This growth will be primarily attributed due to the expected launch of novel, therapies relaxin and LCZ696 during the forecast period. Relaxin is expected to be launched in late 2014 and LCZ696 in 2015. An increase in the treatment seeking population due to an increase in the life expectancy and increasing awareness leading to diagnosis at an early stage will also drive the HF therapeutics market. Apart from these the HF therapeutics market will be driven by the increases in aging population which are more susceptible towards Acute Heart Failure (AHF). The current competition in the HF therapeutics market is weak, primarily dominated by generic drugs such as milirinone, dobutamine, digoxin, Coreg (carvedilol), and Altace (ramipril). Only Diavon (valsartan) and Natrecor (nesiritide) are the two branded product which are expected to lose patents in 2012 and 2014 respectively.

Browse All: Pharmaceuticals Market

Scope
The report provides information on the key drivers and challenges of the Heart Failure therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) Heart Failure therapeutics market revenue data for 2005–2010, and 2011–2018.
- The late stage pipeline has molecules which would affect progression of HF, known as renin inhibitor, Angiotensin receptor neprilysin (ANRI) inhibitor and vasodilators in acute case of heart failure. The other promising drugs in the HF developmental pipeline in terms of mechanism of action include a stem cell therapy, angiotensin converting enzyme inhibitor, aldosterone antagonist, natriuretic peptide receptor agonist, and glucagon-like peptide 1 agonist.
- Analysis of the current and future competition in the key countries of the Heart Failure therapeutics market. Novartis, Amgen, Cardiokline, Bayer, Nile Therapeutics, Cytokinetics, and GlaxoSmithKline are the key players, they are key market players, is covered in this section.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Heart Failure therapeutics market.
- Analysis of key recent licensing and partnership agreements in Heart Failure therapeutics market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Heart Failure therapeutics market.
- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global Heart Failure therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Heart Failure therapeutics market landscape? – Identify, understand and capitalize.